After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

Under his leadership, iTeos raised over $1 billion in capital, completed a successful IPO, and secured a landmark $2 billion partnership with GSK to co-develop and commercialize the company’s ...

Having scored approval for Nucala in COPD, GSK has signed a $12 billion deal to strengthen the pharma’s offering for the respiratory condition.

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and inflammation.

GSK is taking to the airwaves to talk RSV, presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games.

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

Drugmaker GSK will be paid up to £372million after settling a patent row over Covid vaccines in the US. The London-listed pharmaceuticals giant – previously known as Glaxosmithkline – and ...

GSK is sticking to its projection to generate more than 40 billion pounds of sales in 2031, regardless of whether it regains U.S. approval of Blenrep.

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the mRNA vaccine technology that was at the forefront of the world's fight ...